* OncoGenex's stock falls about 54 pct in premarket trading
* Drug fails in late-stage trial as first-line treatment
(Adds details about study, stock movement)
April 28 Teva Pharmaceutical Industries Ltd
and OncoGenex Pharmaceuticals Inc
said their experimental prostate cancer treatment failed to show
improvement over standard chemotherapy in a late-stage trial.
OncoGenex's stock plunged about 54 percent in premarket
trading on Monday.
The study, which enrolled 1,022 patients, tested the
efficacy of the drug in combination with standard chemotherapy,
compared to chemotherapy alone.
The drug, custirsen, did not show statistically significant
improvement in overall survival in patients with previously
untreated metastatic castrate-resistant prostate cancer (mCRPC),
the companies said.
Custirsen, OncoGenex's lead drug candidate, aims to inhibit
the production of the protein clusterin, which may play a
fundamental role in cancer cell survival and treatment
It is also undergoing development as a second-line treatment
for mCRPC, and being evaluated for use in lung cancer.
Bothell, Washington-based OncoGenex's shares were at $4.50
before the bell after closing at $9.70 on the Nasdaq on Friday.
(Reporting by Natalie Grover in Bangalore; Editing by Don
Sebastian and Maju Samuel)